BRAF and melanoma: BRAF inhibitors (BRAFi), such as the BRAFV600E–specific vemurafenib, also known as PLX4032, and dabrafenib, which targets BRAFV600E and also other mutant BRAF variants, significantly prolong overall survival of melanoma patients carrying these mutations 2, 3.